SPI Pharma’s vaccine manufacturing partner Q-Vant achieves EXCiPACT certification

Wilmington, Delaware – September 2026

SPI Pharma  announced that its strategic manufacturing partner, Q-Vant, has successfully achieved EXCiPACT certification, an internationally recognized standard for pharmaceutical excipient manufacturers.

The certification underscores Q-Vant’s commitment to robust quality systems, Good Manufacturing Practices (GMP), and operational excellence. As the manufacturing partner for SPI Pharma’s portfolio of saponin-based vaccine adjuvants for both human and veterinary health, Q-Vant plays a key role in delivering high-quality, reliable solutions to vaccine developers worldwide. Together, SPI Pharma and Q-Vant are the first to offer cGMP QS-21 produced from a sustainable biomass source, combining environmental responsibility with a secure, scalable and secure supply of one of the industry’s most critical vaccine adjuvants.

As demand for advanced vaccine technologies continues to grow, ensuring secure and resilient access to critical raw materials has become increasingly important. The EXCiPACT certification further strengthens confidence in the manufacturing processes, quality systems, and long-term supply capabilities supporting SPI Pharma’s vaccine adjuvant portfolio. Our adjuvant portfolio is already available to customers today, with GMP-grade QS-21 GH and VAC Saponin available now. Valens™ QS-21 XP, our latest addition, is expected to be commercially available by December 2026.

The achievement also represents an important step toward strengthening global pandemic preparedness. Expanding qualified manufacturing capacity for critical vaccine components, while diversifying supply through sustainable sourcing, helps improve the resilience of global vaccine supply chains and supports a faster response to future infectious disease outbreaks.

“Our partnership with Q-Vant is built on a shared commitment to quality, innovation, and sustainability,”

This certification demonstrates the strength of our manufacturing network and reinforces our ability to support vaccine developers with reliable, high-quality adjuvant solutions for both routine immunization programs and future public health needs

Ariana Meirelles, Marketing Manager for Adjuvants, SPI Pharma

SPI Pharma and Q-Vant remain committed to advancing innovative adjuvant technologies while ensuring the highest standards of quality, regulatory compliance, sustainability, and supply reliability. Together, the companies will continue supporting vaccine developers worldwide in bringing the next generation of vaccines to patients and animals around the globe.

Continue reading here

Source: SPI Pharma, website SPI Pharma’s vaccine manufacturing partner Q-Vant achieves EXCiPACT certification

Interested in more information about SPI Pharma excipients?